Europe Sglt2 Inhibitors Market Size & Outlook, 2025-2033
The sglt2 inhibitors market in Europe is expected to reach a projected revenue of US$ 10,508.7 million by 2033. A compound annual growth rate of 6.4% is expected of Europe sglt2 inhibitors market from 2025 to 2033.
- Pharmaceuticals
- Metabolic Disorders Treatment
- SGLT2 Inhibitors Market Outlook
- Metabolic Disorders Treatment
Revenue, 2024 (US$M)
$5,989.3
Forecast, 2033 (US$M)
$10,508.7
CAGR, 2025 - 2033
6.4%
Report Coverage
Europe
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the sglt2 inhibitors market
Every figure cited from GVR research
Europe sglt2 inhibitors market highlights
- The Europe sglt2 inhibitors market generated a revenue of USD 5,989.3 million in 2024.
- The market is expected to grow at a CAGR of 6.4% from 2025 to 2033.
- In terms of segment, jardiance (empagliflozin) was the largest revenue generating drug in 2024.
- Other Drug is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2033.
Europe data book summary
| Market revenue in 2024 | USD 5,989.3 million |
| Market revenue in 2033 | USD 10,508.7 million |
| Growth rate | 6.4% (CAGR from 2025 to 2033) |
| Largest segment | Jardiance (empagliflozin) |
| Fastest growing segment | Other Drug |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Jardiance (Empagliflozin), Farxiga (Dapagliflozin), Invokana (Danagliflozin), Inpefa (Sotagliflozin), Qtern (Dapagliflozin/Saxagliptin), Other Drug |
| Key market players worldwide | Boehringer Ingelheim International GmbH, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson Services, Inc., TheracosBio, Lexicon Pharmaceuticals, Eli Lilly and Company, Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Ltd. |
Other key industry trends
- In terms of revenue, Europe region accounted for 35.6% of the global sglt2 inhibitors market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,154.6 million by 2033.
No credit card required*
Publish Date: Aug 21, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
SGLT2 Inhibitors Market Scope
SGLT2 Inhibitors Market segmentation & scope
SGLT2 Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Bristol-Myers Squibb Company | View profile | - | - | - |
| Johnson & Johnson Services, Inc. | View profile | - | - | - |
| Merck & Co., Inc. | View profile | - | - | - |
| Eli Lilly and Company | View profile | - | - | - |
| Boehringer Ingelheim International GmbH | View profile | - | - | - |
| Glenmark Pharmaceuticals Ltd. | View profile | - | - | - |
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | www.lexpharma.com |
| TheracosBio | View profile | 1-10 | Framingham, Massachusetts, United States, North America | www.theracosbio.com |
Europe SGLT2 Inhibitors Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to SGLT2 Inhibitors Market Outlook will help companies and investors design strategic landscapes.
Jardiance (Empagliflozin) was the largest segment with a revenue share of 61.12% in 2024.
Horizon Databook has segmented the Europe sglt2 inhibitors market based on jardiance (empagliflozin), farxiga (dapagliflozin), invokana (danagliflozin), inpefa (sotagliflozin), qtern (dapagliflozin/saxagliptin), other drug covering the revenue growth of each sub-segment from 2021 to 2033.
- Europe Sglt2 Inhibitors Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Jardiance (Empagliflozin)
- Farxiga (Dapagliflozin)
- Invokana (Danagliflozin)
- Inpefa (Sotagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other Drug
- Europe Sglt2 Inhibitors Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Type 2 Diabetes
- Cardiovascular
- Chronic Kidney Disease (CKD)
- Others
- Europe Sglt2 Inhibitors Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to SGLT2 Inhibitors Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of SGLT2 Inhibitors Market Outlook databook
- Our clientele includes a mix of SGLT2 Inhibitors Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe SGLT2 Inhibitors Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe SGLT2 Inhibitors Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Sglt2 Inhibitors Market, 2021-2033 (US$M)
Europe sglt2 inhibitors market statistics, by drug, 2021-2033 (US$M)
